SCA
ALXN

SAC Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

SAC Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-45,697
Closed -$6.95M – 1192
2014
Q1 		$6.95M Sell
45,697
-21,839
-32% -$3.47M 0.04% 495
2013
Q4 		$8.99M Sell
67,536
-133,734
-66% -$16M 0.05% 393
2013
Q3 		$23.4M Buy
201,270
+111,870
+125% +$12.3M 0.13% 210
2013
Q2 		$8.25M Buy
+89,400
New +$8.62M 0.05% 412

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAC Capital Advisors's ALXN Position: Q2 2014 in Review

SAC Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2014, closing a stake of 45,697 shares — an estimated $6.95M sold.

SAC Capital Advisors first reported a position in ALXN in Q2 2013 and held it in 4 quarters. The position peaked at $23.4M in Q3 2013. 521 funds tracked by Wall St. Rank hold ALXN as of Q2 2014.

  • SAC Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 45,697 Alexion Pharmaceuticals shares in Q2 2014, an estimated $6.95M.
  • SAC Capital Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Alexion Pharmaceuticals position peaked at $23.4M in Q3 2013.
  • 521 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.